Details of the Drug

General Information of Drug (ID: DM4PVDY)

• Drug Name: Durvalumab

Indication

Disease Entry	ICD 11	Status	REF
Urothelial carcinoma	2C92.0	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 3	[2]
Biliary tract cancer	2C17	Phase 2	[2]
Melanoma	2C30	Phase 2	[2]
Pancreatic ductal carcinoma	2C10.0	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Diffuse large B-cell lymphoma	2A81	Phase 1	[2]

• Affected Organisms: Humans and other mammals
• ATC Code:
  L01FF03: Durvalumab
  L01FF: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Monoclonal antibody
• Sequence:
  >heavy chain
  EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYY
  VDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVS
  SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS
  SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEG
  GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
  NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSRE
  EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSR
  WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  >light chain
  EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIP
  DRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIKRTVAAPSVFIFP
  PSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTL
  TLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
• ADMET Property:
  Clearance: The clearance of drug is 8.2 mL/h [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 18 days [3]
  Metabolism: The drug is metabolized via reticuloedothelial system or target-mediated disposition [4]
  Vd: The volume of distribution (Vd) of drug is 5.64 L [3]
• Cross-matching ID:
  UNII: 28X28X9OKV
  DrugBank ID: DB11714
  TTD ID: D0LS9E
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Modulator	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Urothelial carcinoma
• ICD Disease Classification: 2C92.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death 1 ligand 1 (PD-L1)	DTT	CD274	4.38E-07	0.37	2.1

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Durvalumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Durvalumab and Siponimod.	Multiple sclerosis [8A40]	[6]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Durvalumab and Ocrelizumab.	Multiple sclerosis [8A40]	[7]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Durvalumab and Ozanimod.	Multiple sclerosis [8A40]	[8]
Deflazacort	DMV0RNS	Moderate	Additive immunosuppressive effects by the combination of Durvalumab and Deflazacort.	Muscular dystrophy [8C70]	[9]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Drug Products: IMFINZI (durvalumab) injection, for intravenous use
• [4] European Medicines Agency: IMFINZI (durvalumab) Summary of Product Characteristics
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [6] Cerner Multum, Inc. "Australian Product Information.".
• [7] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [8] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [9] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".